Gastric Cancer,Gastrointestinal Cancer Futibatinib in FGFR2-Rearranged Intrahepatic Cholangiocarcinoma: Phase 1/2 Study Feb 24, 2023
Esophageal Cancer,Gastrointestinal Cancer Patient-Reported Outcomes from Mobocertinib Phase 1/2 Study in EGFR+ Metastatic NSCLC: EXCLAIM Extension Cohort Results Feb 24, 2023
Gastrointestinal Cancer,Liver Cancer Analyzing the Exposure-Response of Tremelimumab and Durvalumab in Patients with Unresectable HCC Feb 16, 2023
